Queen Mary University of London

How AI is Transforming Drug Discovery: Bio-IT World Europe Participants to Share Groundbreaking Advances 29-30 November in London

Retrieved on: 
Monday, November 6, 2023
Digital, China Earthquake Networks Center, AstraZeneca, Expert system, Health care, Government, LDN, Conference, Organization, Research, Drug development, Clarivate, Artificial intelligence, MOSAIC, Medicine, Drug discovery, Machine learning, Personalized medicine, RDN, AI, Potential, D, Queen Mary University of London, Medical device, Cancer

LONDON, Nov. 6, 2023 /PRNewswire-PRWeb/ -- The life sciences profession is in the midst of a profound transformation, guided by the revolutionary force of artificial intelligence (AI), and especially predictive and generative AI models. These state-of-the-art technologies are leading the charge—expediting drug discovery and development, catalyzing innovation, and uncovering potential new therapies for cancer, heart disease, and more.

Key Points: 
  • These state-of-the-art technologies are leading the charge—expediting drug discovery and development, catalyzing innovation, and uncovering potential new therapies for cancer, heart disease, and more.
  • "The bio-IT community has always been at the forefront of leveraging AI with the important goal of increasing therapeutic efficacy."
  • In parallel, generative AI refines molecular design with exquisite precision, drastically curtailing the time and resources necessary for drug development.
  • "As general interest in AI explodes, our distinguished speakers have valuable information to share about its evolving role in precision medicine."

J P Jenkins Ltd: DAACI Holdings Shares now trading at JP Jenkins

Retrieved on: 
Tuesday, October 17, 2023
IP, Partnership, Doctorate, Queen Mary University of London, Television, Companies House, SE1, Appointment, AI, Music information retrieval, Artificial intelligence, ISIN, Pedigree, Commercial, Research, Security (finance), Cryptocurrency, Music

17th October 2023 – Shares in DAACI Holdings (www.daaci.com) have been admitted to trade on JP Jenkins share dealing platform.

Key Points: 
  • 17th October 2023 – Shares in DAACI Holdings (www.daaci.com) have been admitted to trade on JP Jenkins share dealing platform.
  • JP Jenkins is a trading name of InfinitX Limited and Appointed Representative of Prosper Capital LLP (FRN453007).
  • The indicative pricing for the ordinary shares (ISIN: GB00BRJ5GB72), as well as the transaction history, will be available on the JP Jenkins website at https://jpjenkins.com/company/daaci-holdings-limited/ .
  • Veronika Oswald, Commercial Director of J P Jenkins said: “We extend our warmest welcome to our esteemed new client DAACI to our share trading platform.

ADVANCING NOVEL CANCER THERAPIES: MOSAIC KEYNOTE PRESENTATION HEADLINES BIO-IT WORLD EUROPE, 29-30 NOVEMBER IN LONDON

Retrieved on: 
Thursday, October 12, 2023
Neoplasm, Senior, Cancer, Partnership, Medicine, Deterministic Barcoding in Tissue for Spatial Omics Sequencing, LDN, Pathology, United Kingdom, Barts Health NHS Trust, Strategic management, Teaching hospital, Consultant, RDN, MOSAIC, Queen Mary University of London, Conference, Research, Medical imaging, Management

LONDON, Oct. 12, 2023 /PRNewswire/ -- A Plenary Keynote address on the first learnings of the $50 million MOSAIC initiative, whose goal is to revolutionize cancer research through spatial omics technologies, will kick off Bio-IT World Conference & Expo Europe, taking place 29-30 November in London.

Key Points: 
  • LONDON, Oct. 12, 2023 /PRNewswire/ -- A Plenary Keynote address on the first learnings of the $50 million MOSAIC initiative, whose goal is to revolutionize cancer research through spatial omics technologies, will kick off Bio-IT World Conference & Expo Europe , taking place 29-30 November in London.
  • This annual gathering fosters collaboration among the United Kingdom's and Europe's medical research, biopharma and technology leaders, who are forging new frontiers in precision medicine together.
  • Spatial omics, combined with AI/ML, will help the partners advance novel therapies for seven difficult-to-treat cancers.
  • "MOSAIC represents the innovations in precision medicine that are only possible when scientific and technology experts collaborate," said Cindy Crowninshield, RDN, LDN, Executive Event Director.

PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) Significantly Improve Overall Survival and Progression-Free Survival in Patients With Previously Untreated Advanced Bladder Cancer in Pivotal Phase 3 EV-302 Trial

Retrieved on: 
Friday, September 22, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Inc., Progression-free survival, RECIST, OS, Bladder cancer, Multimedia, Medicine, PFS, Queen Mary University of London, Death, Carcinoma, Patient, Standard of care, Disease, Brentuximab vedotin, Mortality, FDA, Pembrolizumab, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Safety, Pharmaceutical industry, Medical imaging

The EV-302 trial enrolled patients with previously untreated la/mUC who were eligible for cisplatin- or carboplatin-containing chemotherapy regardless of PD-L1 status.

Key Points: 
  • The EV-302 trial enrolled patients with previously untreated la/mUC who were eligible for cisplatin- or carboplatin-containing chemotherapy regardless of PD-L1 status.
  • View the full release here: https://www.businesswire.com/news/home/20230922521064/en/
    The EV-302 study met its dual primary endpoints of overall survival (OS) and progression-free survival (PFS), compared to chemotherapy.
  • The safety results of the combination are consistent with those of enfortumab vedotin in combination with pembrolizumab previously reported in cisplatin-ineligible patients with la/mUC.
  • The trial is part of an extensive program evaluating this combination in multiple stages of urothelial cancer.

DRIVING PRECISION MEDICINE FORWARD: BIO-IT WORLD EUROPE CONVENES IN LONDON 29-30 NOVEMBER 2023

Retrieved on: 
Thursday, September 21, 2023
Cloud, Partnership, Barts Health NHS Trust, LDN, Data management, Neoplasm, ELIXIR, Biotechnology, Cancer, Biomedical Research, Bioinformatics, Research, RDN, Queen Mary University of London, Government, Organization, Medicine, Drug discovery, Cloud computing, AI, MOSAIC, Conference, FAIR, Pharmaceutical industry

Senior-level scientists and researchers, IT professionals and executives from organizations across life sciences, including pharmaceutical, biotechnology, health systems, academia, government, and national laboratories, will participate in more than 60 sessions in five tracks--R&D in pharma, AI for Pharma, Storage Infrastructure & Cloud Computing, Data Management, and Bioinformatics.

Key Points: 
  • LONDON, Sept. 21, 2023 /PRNewswire/ -- To foster collaboration among the UK and Europe's biopharma and technology leaders who are forging new frontiers in precision medicine, the Bio-IT World Conference & Expo Europe is coming to London 29-30 November 2023.
  • Sessions will showcase the role of AI, FAIR (findable, accessible, interoperable and reusable) data, digital twins, bioinformatics and other technologies in catalyzing progress.
  • Examples include:
    A partnership between Barts Health NHS Trust and Queen Mary University of London, which are investing £600m pounds in a world-leading open-access exascale causal AI computing platform.
  • "Bio-IT World Europe will give participants an exclusive opportunity to network with the people behind the innovations originating in Europe and the UK.

GENE Positioned at the Forefront of Multi-cancer Clinical Utility Research - MRFF Grant names GTG as sole Industry Partner

Retrieved on: 
Monday, September 11, 2023
Cancer, MRFF, University, Royal Melbourne Hospital, Cancer Australia, Bureau of Oceans and International Environmental and Scientific Affairs, National Guideline Clearinghouse, GTG, The Royal Marsden NHS Foundation Trust, Risk, University of Melbourne, Policy, ASX, Breast, Research, Genomics, Prostate, History, Queen Mary University of London, General practice, Standard of care, Melanoma, Genetypes, Scores, Biostatistics, Health, Medical Research Future Fund, Primary care, Pharmaceutical industry, Vaccine

The grant will provide funding for the CASSOWARY Trial: a randomised controlled trial of the clinical utility and cost-effectiveness of a multi-cancer polygenic risk score in general practice.

Key Points: 
  • The grant will provide funding for the CASSOWARY Trial: a randomised controlled trial of the clinical utility and cost-effectiveness of a multi-cancer polygenic risk score in general practice.
  • GTG is the National Research Partner for trial which is to be led by Professor Jon Emery.
  • The trial results will inform future policy including the 5-year goal in the Australian Cancer Plan of using genomics for risk-stratified cancer screening.
  • As the sole industry partner, GTG will receive funding to cover the supply of test kits and the analysis of the sample returned.

Ukraine recap: Yevgeny Prigozhin and the mystery of the mutiny that never was

Retrieved on: 
Thursday, July 6, 2023
M4, Yevgeny Prigozhin, Conversation, University, Curriculum, Kremlin, The Conversation, Intelligence, Institute for the Study of War, Aberystwyth University, Defiant, Parallels, Queen Mary University of London, Revolution, School, Man, F-16, Time, Institute, Wagner Group, Management, Arms industry, Fast food, Airline, Film industry, Cryptocurrency, Air cargo, EU, Prigozhin

But on June 24, at least some Russian troops moved much more rapidly toward their own capital.

Key Points: 
  • But on June 24, at least some Russian troops moved much more rapidly toward their own capital.
  • Barely had our ink dried when Prigozhin led 25,000 of his troops back into Russia.
  • Putin vowed a “harsh response” to Prigozhin and those who were joining the Wagner Group boss up the M4 highway towards Moscow.
  • Prigozhin, who apparently agreed to relocate to Belarus, seems to be free to move between the two countries with a degree of security.
  • Read more:
    Failed Wagner Group coup leaves Putin humiliated and Belarus dictator Lukashenko more secure – for now

Meanwhile in nearby Vilnius

    • Finland has successfully acceded to membership of the alliance, hugely extending Nato’s border with Russia.
    • But he may be mollified if the US changes its mind over the supply of F-16 fighter jets.
    • Read more:
      Nato: Vilnius summit will reflect fresh sense of purpose over Ukraine war – but hard questions remain over membership issues

Parallels with the past

Ukraine recap: counteroffensive makes slow progress while diplomacy fails to make any ground at all

Retrieved on: 
Thursday, June 22, 2023
Yevgeny Prigozhin, Conversation, University, ISW, English, Internet, Politics, Kremlin, The Conversation, Institute for the Study of War, Carbon, Queen Mary University of London, Government, Wind, University of Portsmouth, Grain, Red Sea, Ministry, Volodymyr Zelenskyy, Institute, Copenhagen, Conventional weapon, Chatham House, University of Copenhagen, Republican, Sciences Po, News, Wagner Group, Farm, Prigozhin, Arms industry, Communications satellite, Whaling, Sergei Shoigu, Chernyshov

One expert pondering the timing of the counteroffensive is Cyrille Bret, an expert in defence studies at Sciences Po, who asks: why now and to what end?

Key Points: 
  • One expert pondering the timing of the counteroffensive is Cyrille Bret, an expert in defence studies at Sciences Po, who asks: why now and to what end?
  • But there are other factors – strategic and political – that would have driven Zelensky to give the order to begin.
  • It could be awkward, to say the least, writes Tracey German, a professor of conflict and security at King’s College London.
  • Read more:
    Ukraine war: Kremlin attempt to control private militaries like Wagner Group fails to address rivalry between factions

From the sky to the seabed

    • Christopher Morris, who teaches military strategy at the University of Portsmouth, believes access to superior commercial satellite tech has given Ukraine a significant edge in targeting Russian armour.
    • Hi-res images of Russian defensive installations will allow Ukraine’s planners to work out ways to target, destroy or circumvent them.
    • Read more:
      Ukraine war: Kremlin's threat to interfere with undersea data cables may be bluster, but must be taken seriously

Neighbourhood threat

    • Vladimir Putin announced the other day to let us know he planned to station nuclear warheads in neighbouring Belarus.
    • Belarus was the first former Soviet bloc country to get rid of its nukes after the collapse of the Soviet Union.
    • Since the late 1990s, the two countries have been what’s known as a “union state” (read, decisions are taken mainly in Moscow).
    • Read more:
      Ukraine war: Russia's threat to station nuclear warheads in Belarus – what you need to know

Prospects for peace?

International Greenwich Olympiad (IGO2023): Inspiring Excellence in Innovation

Retrieved on: 
Wednesday, June 21, 2023
Park, IGO, College, Exhibition, Buckingham Palace, London Eye, Leicester Square, Oxford Street, Regent's University London, Hyde Park, Student, Regent's Park, Museum, Queen Mary University of London, QMUL, Knowledge, King's College, Interior design, Tourism, Harrods

LONDON, June 21, 2023 /PRNewswire/ -- The International Greenwich Olympiad (IGO2023), organised and sponsored by North London Grammar School (NLGS), concluded on 18th June in London, UK.

Key Points: 
  • LONDON, June 21, 2023 /PRNewswire/ -- The International Greenwich Olympiad (IGO2023), organised and sponsored by North London Grammar School (NLGS), concluded on 18th June in London, UK.
  • Partnering with the prestigious Queen Mary University London for accommodation arrangements, IGO2023 provided participants with a unique opportunity to experience the facilities designed for aspiring university students.
  • The esteemed judges were astounded by the calibre of projects on display, commenting on the high level of promise demonstrated by several entries.
  • The IGO will continue to serve as a platform for young innovators and visionaries from across the globe to showcase their remarkable projects, fostering a spirit of collaboration and inspiring excellence in innovation.

Dompé Foundation Doubles Its Funding for Rita Levi Montalcini fellowships in Neuroscience and Neurobiology

Retrieved on: 
Tuesday, June 20, 2023
Mental Health, Health, Other Health, Other Science, Research, Science, Biotechnology, Call, Bocconi University, Ambassador, University of Pittsburgh, University, Digital Public Library of America, Education, Stanford University, Public, Multimedia, Washington University in St. Louis, Female, Queen Mary University of London, Georgetown University, Doctor of Philosophy, Harvard Medical School, Student, Johns Hopkins University, Investment, MA, STEM, Sarnoff Fellowship, Weill Cornell Medicine, Memory, University of Chicago, Pharmaceutical industry, Management, Nursing, Neuroscience, Yale University, Medicine

The Dompé Foundation has announced it doubled to 1 million dollars its support to MA, PhD and post-doc candidates from United States-based universities for 2023.

Key Points: 
  • The Dompé Foundation has announced it doubled to 1 million dollars its support to MA, PhD and post-doc candidates from United States-based universities for 2023.
  • As with former grants, the Foundation will offer scholarships and fellowships to the most promising candidates.
  • "Investment in young researchers is a guarantee of success in terms of scientific discoveries and economic progress," Ambassador Zappia pointed out in expressing appreciation for the opportunities provided by the Dompé Foundation.
  • The Foundation’s commitment to the progress of scientific knowledge is part of Dompé farmaceutici’s long lasting investments in R&D and innovative startups.